Incretin Pathway Comparator Kit research kit - MiPeptidos

Resumen de Investigación de Incretin Pathway Comparator Kit

Descarga gratuita — resumen bibliográfico en PDF

Resumen bibliográficoDatos HPLCPMIDs + citasEN + ES

Sin spam. Cancela en cualquier momento.

Prueba analítica

Pureza por lote, justo donde los investigadores la buscan.

Cada compuesto incluido muestra su resultado HPLC, referencia de lote y fecha de prueba para que el research brief esté respaldado por evidencia analítica real.

Semaglutide

Pureza (HPLC)

99.1%

HR-SMGL-2600315

RP-HPLC C18January 21, 2026

Tirzepatide

Pureza (HPLC)

99.2%

HR-TRZP-2600315

RP-HPLC C18January 2, 2026

Investigación MetabólicaSave 10%

Incretin Pathway Comparator Kit

Name: Incretin Pathway Comparator Kit — Peptide Research Kit
Brand: MiPeptidos
Price: 280.71 USD
Availability: InStock

Pairs the two most visible incretin-pathway compounds in modern published literature

Combina los dos principales agonistas de la vía GLP-1 estudiados en ensayos publicados importantes.

Semaglutide anchors the single-receptor GLP-1 literature

Tirzepatide extends the comparison into dual GIP/GLP-1 signaling

Useful for studying single- versus dual-incretin trial design

Built around compounds examined in large modern metabolic studies

Solo para Uso en Investigación.

Solo para Uso en Investigación. Estos kits están destinados únicamente para fines de investigación en laboratorio. No para consumo humano. Los resúmenes públicos reflejan literatura publicada y documentación analítica, no instrucciones de uso humano ni claims terapéuticos.

Paquete de Kit

USD 280.71

USD 311.90

Ahorra USD 31.19 (10% off)

Semaglutide (10mg)

USD 86.95

Tirzepatide (10mg)

USD 224.95

COA Incluido

Verificado por HPLC

Envío el Mismo Día

Pruebas de Terceros

Transacciones Seguras· SSL de 256 bits

Crypto

COA Incluido

|Verificado por HPLC

|Cumple con GMP

|Pruebas de Terceros

|Envío el Mismo Día

|Lote Rastreado

Resumen de evidencia

Construido desde investigación publicada, no desde suposiciones.

Cada kit público ahora abre con la prueba: estudios citados, PMIDs, señales rastreadas y documentación por lote en cada componente.

Revistas destacadas

The New England Journal of Medicine

Ventana de observación

16 semanas

Fases de estudio

Endpoints rastreados

Rango de publicación

2016-2022

Estudios destacados

PMIDs en página

Señales de investigación

COAs incluidos

Lo que suelen seguir los investigadores

Mediciones, marcadores y lecturas comunes asociadas con esta línea de investigación en la literatura publicada.

Fasting glucoseHbA1c baselineAppetite VASHOMA-IRFasting insulinCaloric intakeBody weightWaist circumference

Arquitectura del compuesto

Qué hay dentro del kit, a nivel estructural

Detalles químicos clave tomados de cada compuesto incluido para que la página se sienta como un perfil de investigación real, no como una tarjeta genérica de bundle.

Semaglutide

CAS: 910463-68-2

Semaglutide is a GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release. The Aib substitution at position 2 confers resistance to DPP-IV enzymatic degradation, and the C18 fatty diacid chain enables high-affinity albumin binding, extending its half-life substantially. It also acts on hypothalamic appetite centers to reduce food intake and delay gastric emptying.

Fórmula molecular

C187H291N45O59

Peso molecular

4113.64 Da

Secuencia

Modified GLP-1(7-37) analog; 31 amino acids with Aib at position 8, Arg at position 34, and a C18 fatty diacid chain via linker at Lys26

Tirzepatide

CAS: 2023788-19-2

Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. It stimulates insulin secretion, suppresses glucagon in a glucose-dependent manner, and reduces appetite via central and peripheral signaling. The dual receptor engagement provides synergistic metabolic effects beyond GLP-1 agonism alone, including enhanced lipid metabolism and improved insulin sensitivity.

Fórmula molecular

C225H348N48O68

Peso molecular

4813.45 Da

Secuencia

39-amino acid peptide based on GIP sequence with Aib at positions 2 and 13, and a C20 fatty diacid chain conjugated to Lys20 via a linker; C-terminal amidation

Parámetros de estudio publicados

Rangos de dosis, intervalos y rutas de administración citados típicamente en la literatura para los compuestos de este kit.

Notas del Protocolo de Investigación

These peptides are typically used one at a time, not simultaneously. Published sequencing protocols begin with Semaglutide to establish baseline, followed by Tirzepatide if a dual-agonist approach is preferred. Published protocols use gradual titration to minimize GI side effects.

Semaglutide

Same day each week

Rangos de dosis citados

0.25mg → 2.4mg

Intervalos citados

Once weekly

Rutas citadas

Subcutaneous (abdomen or thigh)

Tirzepatide

Same day each week

Rangos de dosis citados

2.5mg → 15mg

Intervalos citados

Once weekly

Rutas citadas

Subcutaneous (abdomen or thigh)

Estos son parámetros de estudio resumidos a partir de literatura citada y diseños de investigación. Se presentan solo como contexto de investigación, no como instrucciones ni recomendaciones de uso humano.

Investigación Publicada

Papers revisados por pares que respaldan los compuestos y la lógica de combinación de este kit.

The New England Journal of Medicine2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

Wilding JPH, Batterham RL, Calanna S, et al.

Published data demonstrated 14.9% mean body weight reduction with Semaglutide 2.4 mg weekly vs. 2.4% with placebo over 68 weeks in participants with overweight or energy-balance research.

PMID: 33567185

The New England Journal of Medicine2022

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

Jastreboff AM, Aronne LJ, Ahmad NN, et al.

In peer-reviewed research, Tirzepatide at 15 mg weekly demonstrated mean weight reductions of 22.5% at 72 weeks, the largest weight reduction observed with a pharmacological agent in published trial data.

PMID: 35658024

The New England Journal of Medicine2021

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)

Frias JP, Davies MJ, Rosenstock J, et al.

Published head-to-head data demonstrated Tirzepatide superiority over Semaglutide in HbA1c reduction and body weight change, with dual GIP/GLP-1 activation producing enhanced metabolic outcomes.

PMID: 34170647

The New England Journal of Medicine2016

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)

Marso SP, Bain SC, Consoli A, et al.

Literature demonstrates Semaglutide produced a 26% reduction in major adverse cardiovascular events in published trial data, establishing cardiovascular research interest beyond glucose-regulation research.

PMID: 27633186

Lo que suelen seguir los investigadores

Mediciones, marcadores y lecturas comunes asociadas con esta línea de investigación en la literatura publicada.

Body weight & BMI — primary outcome in published trials

HbA1c — glycemic control marker (target < 7.0%)

Fasting glucose & insulin — metabolic function markers

Lipid panel (LDL, HDL, triglycerides) — cardiovascular risk

Waist circumference — visceral adiposity surrogate

Appetite VAS (Visual Analog Scale) — satiety assessment

Lo observado en la literatura

Una vista en lenguaje claro de cómo suelen desarrollarse las ventanas de estudio, los marcadores y los cambios reportados dentro de esta línea de investigación.

Weeks 1-2Semaglutide · Tirzepatide

Receptor Engagement & Titration Initiation

Fasting glucoseHbA1c baselineAppetite VAS

Published STEP trial data documented initial GLP-1 receptor engagement with appetite modulation observed in the majority of study participants within 7-14 days

In peer-reviewed studies, low-dose titration of Semaglutide (0.25 mg/week) demonstrated early satiety signaling signaling changes without significant GI disturbance in most subjects

Literature demonstrates Tirzepatide's dual GIP/GLP-1 engagement producing complementary incretin effects from the first administered dose in SURPASS trial cohorts

Weeks 3-4Semaglutide · Tirzepatide

Dose Escalation & Metabolic Adaptation

HOMA-IRFasting insulinCaloric intake

Published research observed dose-dependent increases in insulin sensitivity markers following standard titration protocols in both STEP and SURPASS studies

In peer-reviewed studies, GLP-1 receptor activation demonstrated hepatic glucose output modulation, with measurable fasting glucose changes in study cohorts

Literature demonstrates Tirzepatide's GIP receptor co-activation producing enhanced beta-cell responsiveness compared to GLP-1-only approaches in published head-to-head data

Weeks 5-8Semaglutide · Tirzepatide

Active Metabolic Response Phase

Body weightWaist circumferenceVisceral fat (DEXA)

Published STEP 1 trial data documented mean body weight reductions of 5-7% by

In peer-reviewed SURPASS trials, Tirzepatide demonstrated superior glucose-regulation research markers compared to selective GLP-1 agonists at equivalent timepoints

Literature demonstrates measurable changes in visceral adipose tissue distribution as assessed by DEXA in published body composition substudies

Weeks 9-10Semaglutide · Tirzepatide

Cardiovascular & Lipid Marker Changes

LDL-CTriglycerideshs-CRPBlood pressure

Published research observed significant modifications in lipid panel markers including LDL-C, triglycerides, and HDL-C in study populations by this timepoint

In peer-reviewed SELECT trial data, Semaglutide demonstrated cardiovascular outcome research interest independent of weight-change markers in high-risk cohorts

Literature demonstrates reductions in systolic blood pressure of 4-6 mmHg in published SURPASS trial data during this protocol phase

Weeks 11-13Semaglutide · Tirzepatide

Body Composition Remodeling

Lean mass (DEXA)Visceral fat ratioHbA1c

Published STEP trial data documented continued linear weight reduction with mean losses of 10-14% from baseline in the active treatment arm

In peer-reviewed studies, Tirzepatide at highest titrated doses demonstrated up to 22.5% mean weight reduction in the SURPASS-II cohort

Literature demonstrates preferential reduction in visceral adipose tissue with relative preservation of lean mass in published DEXA substudies

Weeks 14-15Semaglutide · Tirzepatide

Metabolic Stabilization

ALTLiver fat (MRI)SF-36 scores

Published research observed plateau effects in body weight trajectory indicating new metabolic setpoint establishment in study cohorts

In peer-reviewed studies, sustained GLP-1/GIP receptor activation demonstrated maintained appetite suppression without significant tachyphylaxis at stable doses

Literature demonstrates improvements in hepatic steatosis markers including ALT normalization and liver fat content reduction in published MRI substudies

Week 16Semaglutide · Tirzepatide

Protocol Endpoint Assessment

Total weight changeHbA1c changeLipid panelHOMA-IR

Published STEP and SURPASS trial endpoints documented comprehensive metabolic improvements across glycemic, lipid, and body composition markers at 16 weeks

In peer-reviewed research, comparative analysis of Semaglutide vs. Tirzepatide provided data on differential receptor-activation outcomes at equivalent timepoints

Literature demonstrates that published trial data supports assessment of continued administration vs. dose modification based on individual response markers

Manejo y documentación

Detalles de manejo del material y documentación por lote que respaldan flujos de trabajo de investigación más limpios.

Water Volume

2 mL bacteriostatic water per 10mg vial

Concentration

5 mg/mL — titrate from 0.25 mg/week according to published protocols

Storage

Refrigerate at 2-8°C after reconstitution. Stable for up to 42 days. Do not freeze.

Por qué existe este kit

Por qué estos compuestos se combinan en la literatura

Resúmenes en lenguaje claro de los mecanismos y combinaciones publicadas que hacen que este kit tenga sentido para investigación real.

Semaglutide

Semaglutide is a GLP-1 receptor agonist studied extensively in the STEP clinical trials, demonstrating significant effects on appetite-signaling research and metabolic markers (PMID: 33567185).

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The SURPASS trials showed it acts on two incretin pathways simultaneously, with notable findings in metabolic research (PMID: 35658024).

Having both compounds available allows researchers to compare single vs. dual-receptor approaches, or study sequential administration patterns.

Péptidos Incluidos

Qué Incluye Este Kit

2 péptidos, cada uno con documentación COA individual

Semaglutide

$86.95

glucose-regulation research glucose-regulation research · energy-balance research and metabolic signaling research · cardiometabolic research in diabetic populations

Semaglutide is a GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release.

10mgGLP-1 / Weight Management

Tirzepatide

$224.95

glucose-regulation research with superior HbA1c reduction · energy-balance research treatment with significant metabolic research outcomes · Dual incretin receptor pharmacology studies

Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously.

10mgGLP-1 / Weight Management

Lectura por péptido

Ver Todos los Kits de Investigación →

15% off

Kit Comparador Triple de Incretinas

Agonistas únicos, duales y triples — los tres compuestos estudiados en los ensayos STEP, SURPASS y NEJM Fase 2

3 peptides · Investigación Metabólica

$407.85$346.67

Save $61.18

12% off

Kit de Estudio de Vías Lipolíticas

Tres mecanismos lipolíticos estudiados en investigación publicada — actividad de fragmento HGH más oxidación mitocondrial

3 peptides · Investigación Metabólica

$134.90$118.71

Save $16.19

12% off

Kit de Investigación en Reparación Tisular

Los dos péptidos de reparación tisular más citados, estudiados juntos en la literatura publicada

2 peptides · Investigación Tisular

$167.90$147.75

Save $20.15

Ver Todos los Kits de Investigación →

Comienza tu Investigación

Get the complete Incretin Pathway Comparator Kit at $280.71 — save $31.19 versus purchasing each compound separately. Full COA documentation included with every vial.

Elige tu Opción Explorar Todos los Kits de Investigación